# EDGAR Filing Document

**Accession Number:** 0001016504
**File Stem:** 0001345281-26-000007
**Filing Date:** 2026-4
**Character Count:** 9563
**Document Hash:** 6979eee62b317f376da46cecd1b3b8ed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001345281-26-000007.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001345281-26-000007

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTEGRATED BIOPHARMA INC
- **CENTRAL INDEX KEY:** 0001016504
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 222407475
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52311
- **FILM NUMBER:** 26871361

**BUSINESS ADDRESS:**
- **STREET 1:** 225 LONG AVENUE
- **STREET 2:** BUILDING 15
- **CITY:** HILLSIDE
- **STATE:** NJ
- **ZIP:** 07205
- **BUSINESS PHONE:** 9739260816

**MAIL ADDRESS:**
- **STREET 1:** 225 LONG AVENUE
- **STREET 2:** BUILDING 15
- **CITY:** HILLSIDE
- **STATE:** NJ
- **ZIP:** 07205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTEGRATED HEALTH TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20020912

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEM INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 19960716
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DeSantis Damon
- **CENTRAL INDEX KEY:** 0001889279

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 109 SE 5TH AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** DELRAY BEACH
- **STATE:** FL
- **ZIP:** 33483

### Attached PDF Documents

**Attachment 1:** `Joint_Filing_Agreement_CDDS.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**INTEGRATED BIOPHARMA INC**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Damon DeSantis**<br>109 SE 5th Avenue<br>Second Floor<br>Delray Beach FL 33483<br>561-278-1169

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/15/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**DeSantis Damon** | Name of reporting person<br>**DeSantis Damon** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**187500.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12733058.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**187500.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12733058.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12920558.00** | Aggregate amount beneficially owned by each reporting person<br>**12920558.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**41.3%** | Percent of class represented by amount in Row (11)<br>**41.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CDDS 2.0, LLC** | Name of reporting person<br>**CDDS 2.0, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**FLORIDA** | Citizenship or place of organization<br>**FLORIDA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**12733058.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**12733058.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12733058.00** | Aggregate amount beneficially owned by each reporting person<br>**12733058.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**41.0%** | Percent of class represented by amount in Row (11)<br>**41.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
INTEGRATED BIOPHARMA INC

**(c) Address of Issuer's Principal Executive Offices:**
225 LONG AVENUE, BUILDING 15, HILLSIDE, NJ, 07205

**Item 4. Purpose of Transaction**

No member of the Group has a present intention or plans or proposals which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Notwithstanding anything to the contrary contained herein, each member of the Group reserves the right, depending on all relevant factors, to change their intentions with respect to any and all of the matters referred to above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
After giving effect to the transfers described in Item 3:

(i)	CDDS is the record and beneficial owner of 12,733,058 shares of Common Stock, representing approximately 41.0% of the outstanding shares of Common Stock (based on 31,059,610  shares of Common Stock outstanding as of April 15, 2026).

(ii)	DeSantis is the beneficial owner of an aggregate of 12,920,558 shares of Common Stock, representing approximately 41.3% of the outstanding shares of Common Stock (based on 31,059,610 shares of Common Stock outstanding as of April 15, 2026).  DeSantis does not directly hold the shares of Common Stock described in the transfers set forth in Item 3.  DeSantis directly holds 187,500 shares of Common Stock in the form of presently exercisable stock options.

**(b)**
(i)	CDDS has sole voting power and sole dispositive power with respect to the 12,733,058 shares of Common Stock.

(ii)	Through control of CDDS, DeSantis has shared voting power and shared dispositive power with respect to the 12,733,058 shares of Common Stock described in Item 3.  DeSantis has sole voting power and sole dispositive power with respect to the 187,500 shares of Common Stock beneficially owned by DeSantis.

**(c)**
Except for the transactions described in Item 3, neither member of the Group has effected any transaction in the shares of Common Stock subject hereof during the sixty (60) days prior to the date of this Statement.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Neither member of the Group has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer of voting of securities, finder's fees, joint venture, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses or the giving or withholding of proxies, other than stock options issued by the Issuer to DeSantis.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** DeSantis Damon

**Signature:** /s/ Damon DeSantis

**Name/Title:** Damon DeSantis/Individual

**Date:** 04/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CDDS 2.0, LLC

**Signature:** /s/ Damon DeSantis

**Name/Title:** Damon DeSantis/Sole Member

**Date:** 04/17/2026